Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA
EXTON, Pa., July 31 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the wave one LaunchTrends (TM): SIMPONI and CIMZIA report. The survey was completed by U.S. Rheumatologists
in late June 2009.
While awareness of both new TNF antagonists is relatively h...
For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia
WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthrit...
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
EXTON, Pa., June 4 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the baseline LaunchTrends (TM): SIMPONI report. The survey was completed by U.S. Rheumatologists
in May 2009, just days after the FDA announced approval for SIMPONI (golimumab).
Once monthly dos...
As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources
WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of th...
Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis
However, Pharmacy Directors Disagree About Formulary Inclusion for Key
Emerging Biologic Agents That Will Launch for the Disease in the Next Few Years, According to a New Report from Decision Resources
WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the
Geisinger rheumatologists redesign osteoporosis, rheumatoid arthritis care
DANVILLE, PA. With the nation collectively spending about $18 billion per year on osteoporosis related bone fractures, Geisinger researchers found that streamlining the ordering process for osteoporosis bone density scans quadrupled the number of patients who received the exam.
An estimated 10...
UT rheumatologists discover 2 genes related to disabling form of arthritis
HOUSTON (Oct. 22, 2007)Work done in part by researchers at The University of Texas Medical School at Houston has led to the discovery of two genes that cause ankylosing spondylitis, an inflammatory and potentially disabling disease. The findings are published in the Oct. 21 online edition of Nat...
Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013
...Rheumatoid Arthritis in Brazil also finds that survey results of Brazilian rheumatologists
show regional differences in their preferences for agents within key drug c...brel emerges as the patient share leader among biologics in Rio de Janeiro, rheumatologists
from Sao Paulo and Belo Horizonte prefer Humira and Remicade, respectively....
Vivacare Patient Education Service Enhancements Save Medical Practices Time and Money and Improve Patient Satisfaction
...care has developed services to meet the practice needs of 12 medical specialties, including allergists, cardiologists, dermatologists , neurologists, rheumatologists
and primary care physicians.
### Read the full story at http://www.prweb.com/releases/medical-practices/save-money/prweb2580674.htm . ...
Over half of people with rheumatoid arthritis have periodontitis
...ions involving inflammatory rheumatic disease (especially RA), cardiovascular disease and diabetes. However, further cross-disciplinary research among rheumatologists
and periodontologists is required to fully understand the underlying mechanisms that link RA and periodontitis, and to explore how patients can be man...
Rheumatologists in Medical Technology
Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Ferring Pharmaceuticals Presents Study at the Annual Scientific Meeting of the American College of Rheumatology
BOSTON, Nov. 7 /PRNewswire/ -- Ferring Pharmaceuticals presented the
results of a cost-utility study supporting the adoption of EUFLEXXA(TM) (1%
sodium hyaluronate) i...
New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
...R) is a three wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 rheumatologists
and Primary Care Physicians will participate in the research. Following a baseline report, three additional waves will be published capturing launch ...
New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis
...c pathways that drive RA development and generate tissue damage. Dr. Rosen and his team of researchers are working to define new blood tests to help rheumatologists
diagnose RA in its early stages, which will improve their ability to predict which patients will develop worse joint destruction, and potentially pr...
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
...cy, safety and tolerability, respectively, are
inferior to those of Enbrel-and efficacy, safety and tolerability are
weighted more heavily by surveyed rheumatologists
as key drivers of
prescribing decisions," said Cindy Mundy, Ph.D., director at Decision
Resources. "As a result, the improvements in dosing frequency ...
Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
As part of the sponsorship, the Arthritis Foundation will launch a new
program in which the organization will reach out to rheumatologists
members of the Association of Rheumatology Health Professionals in an
effort to help boost attendance and awareness of the Arthritis Walk by
New Phase IV Clinical Study Indicates LidoSite Provides
Rheumatology Patients Superior Pain Relief
...t options, such as
ethyl chloride, lidocaine injections or fluormethane spray.
"This initial study demonstrates the acceptability among
patients and rheumatologists
for using LidoSite as an effective
treatment regime for needle pain for the multiple injections
arthritis requires, as well as its potential availabil...
Rheumatologists in Biological News
Gene expression findings a step toward better classification and treatment of juvenile arthritis
...is patients, who frequently have a positive ANA, than to the other subgroups of polyarticular JIA.
Dr. Colbert says the new findings take pediatric rheumatologists
a step closer to more precisely classifying JIA, and eventually developing individually tailored treatments that maximize the benefits, while minimizi...
Musculoskeletal center wins $2.2 million for drug safety
...or in the Division of Clinical Immunology and Rheumatology. Biologics have become a premier treatment for serious inflammatory conditions diagnosed by rheumatologists
and other specialists.
"These medicines have revolutionized the way chronic inflammatory disease is treated, and they have benefited millions of pa...
New guidelines for treating rheumatoid arthritis
...mage and disability.
The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists
and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was pu...
Rheumatologists in Biological Technology
Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
EXTON, Pa., Sept. 17 /PRNewswire/ -- BioTrends Research Group, Inc.
released its third annual TreatmentTrends(TM): The Use of Biologic Agents
in Rheumatology publication, providing insight into the management of
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing
New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives
...ered at a special roundtable discussion between several of Europe's leading rheumatologists
and RA patients representing key advocacy organizations from the United Kin...patients' viewpoints and expectations can provide a valuable perspective to rheumatologists
and help shape our management and treatment strategies."
In addition t...
Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)
...The research is based on results of a survey of 77 rheumatologists
conducted on-line between May 5th and May 7th.
95% of the rheumatologists
surveyed were aware of SIMPONI and about one-third...patients as soon as it is available.
are also highly aware of other late stage biologic...
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
...erious side-effects associated with those drugs."
Dr. Rosenbaum noted that a poster presentation at ARVO from a survey of U.S. ophthalmologists and rheumatologists
from 27 states, presented by researchers from the Wilmer Eye Institute of Johns Hopkins University, Baltimore, found that the dose of oral corticoster...
Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Institute. "Offering once-monthly subcutaneous dosing, SIMPONI will provide
an important and convenient new treatment option to rheumatologists
patients. SIMPONI expands our leading immunology franchise in meeting the
needs of the rheumatology community."
Centocor Ortho Biotec...
Patients Who Bring Health Information from the Internet Get More Time with Doctor
...rgeons, Pediatricians, Primary Care Physicians (General Practice, Family Practice and Internal Medicine), Psychiatrists, Pulmonologists, Radiologists, rheumatologists
Other Manhattan Research Products and Services
Manhattan Research conducts annual research studies among physicians and consumers...
Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
... & Analysis:
Rheumatoid Arthritis Q1 2008, MedPredict's global Thought Leader Panel
debates tough questions facing drug developers:
-- How should rheumatologists
sequence/stack biologicals? What will challenge the anti-TNF paradigm? T-cell? B-cell? Mesenchymal cell? -- How big of a benefit will oral do...
Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007
... Orthopedic Surgeons and rheumatologists
Performing More Procedures
WALTHAM, Mass., Nov. ...e period, average quarterly HA knee injections
increased from 54 to over 75. Fueling this growth ...product
efficacy as their number one reason, while rheumatologists
long-term pain relief as their first prio...
Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
...l expand through mid-2008.
Seventy-two percent of dermatologists and 90% of rheumatologists
will write more scripts for biologics for psoriasis and psoriatic
...ding Biologics Landscape is
based on a U.S. survey of 50 dermatologists, 51 rheumatologists
managed care pharmacy directors. Their responses were compared to as...